This special series on Epidemiology, Biomarkers and Modelling of Gastroesophageal Reflux Disease is co-edited by Dr. Peter W. Dettmar from Technostics Ltd & RD Biomed Ltd, Castle Hill Hospital, East Yorkshire, UK; and Dr. Jeffrey Pearson from Newcastle University Biosciences institute, The Medical School, Framlington Place, Newcastle upon Tyne, UK.
Peter W. Dettmar, PhD, CBiol, FSB, FRSPH
Technostics Ltd & RD Biomed Ltd, Castle Hill Hospital, East Yorkshire, UK
Prof. Peter Dettmar is the MD of Technostics Limited and RD Biomed Limited, Castle Hill Hospital, Cottingham, East Yorkshire UK and is the former global Research and Development Director - Gastrointestinal for Reckitt Benckiser Healthcare (UK) Limited with extensive experience in running product development programs and clinical trials and over forty years’ experience of the pharmaceutical and healthcare industries. He has an Honorary Professorship with the School of Pharmaceutical Sciences University of Nottingham, UK.
Prof. Dettmar is a named inventor on over 40 patents, has supervised more than 70 successful PhD. studentships and has authored or co-authored over 550 scientific and clinical publications. Prof. Dettmar has special research interests in reflux disease, pepsin, mucosal protection, bioadhesion, H. pylori, nutrition, dietary fibres/functional foods, Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), polymers/biopolymers, cell biology and has established international research and clinical networks that are core to research in these areas.
Jeffrey Pearson, PhD
Newcastle University Biosciences institute, The Medical School, Framlington Place, Newcastle upon Tyne, UK
Professor Jeffrey Peter Pearson graduated with a PhD from Charing Cross medical school London U.K. in 1977 and then held several posts in the department of Physiological Sciences Newcastle University U.K. He was appointed Professor of Molecular Physiology in 2002. He has authored over 100 scientific publications and is a reviewer for several international journals. He has supervised over 35 PhD students to successful completion. He also holds several international patents.
His research areas deal with the fields of Gastrointestinal Physiology, mucosal protection, biopolymers and food trials. His research interests also include diseases/ problems associated with gastrointestinal reflux i.e. Idiopathic pulmonary fibrosis, Chronic obstructive pulmonary disease, Glue ear, sinusitis, rhinitis and lung transplant rejection. In particular the role of pepsin. He is currently involved in developing models to study Drug delivery and has spun out a company Aelius Biotech in July 2019.
- Review of the Global Prevalence of Gastroesophageal Reflux Disease (GERD)
- Pepsin as a biomarker for self-diagnosing reflux associated symptoms in UK and USA individuals
- Pepsin properties, structure and its accurate measurement
- Pepsin and pH of gastric refluxate in patients diagnosed with upper gastrointestinal diseases
- The potential role of a dysregulated aerodigestive microbiome in chronic lung disease
- In vitro modelling of the upper digestive tract and airways
- The rheological properties of an alginate satiety formulation in a physiologically relevant Human Gut Model Gut System
- Development of an infant stomach model: validation of products targeting reflux in babies and infants
The series “Epidemiology, Biomarkers and Modelling of Gastroesophageal Reflux Disease” was commissioned by the editorial office, Annals of Esophagus without any sponsorship or funding. Peter W. Dettmar and Jeffrey Pearson are serving as the unpaid Guest Editors for the series.